Sanofi Licenses Kali’s Tri-Specific Antibody in $1B Deal
Kali Therapeutics has entered into a licensing agreement with Sanofi for the development of a novel tri-specific T-cell engager, KT501, aimed at treating a broad range of B…
Read More...
Read More...
